Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin

This is the first case report of alectinib as a bridge to allo‐SCT in a patient with ALK‐positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis. This is the first case report of alectinib as a bridge to allo‐SCT in a...

Full description

Saved in:
Bibliographic Details
Published inClinical case reports Vol. 7; no. 12; pp. 2500 - 2504
Main Authors Nakai, Ritsuko, Fukuhara, Suguru, Maeshima, Akiko Miyagi, Kim, Sung‐Won, Ito, Yuta, Hatta, Shunsuke, Suzuki, Tomotaka, Yuda, Sayako, Makita, Shinichi, Munakata, Wataru, Suzuki, Tatsuya, Maruyama, Dai, Izutsu, Koji
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.12.2019
John Wiley and Sons Inc
Wiley
Subjects
alectinib
ALK‐positive ALCL
Back pain
Bone marrow
Case Report
Case Reports
Chemotherapy
hematopoietic stem cell transplantation
Immunotherapy
Kinases
Lymphatic system
Lymphoma
Medical imaging
Medical prognosis
Metabolism
Monoclonal antibodies
NMR
Nuclear magnetic resonance
Patients
Radiation therapy
Stem cells
Targeted cancer therapy
Transplants & implants
Japan
hematopoietic stem cell transplantation
ALK‐positive ALCL
alectinib
Online AccessGet full text

Cover

More Information
Summary:This is the first case report of alectinib as a bridge to allo‐SCT in a patient with ALK‐positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis. This is the first case report of alectinib as a bridge to allo‐SCT in a patient with ALK‐positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.2543